Our results indicate a presurgical SRL therapy interplay with TICs in somatotroph adenomas and show that the CD68+/CD8+ ratio is a biomarker for treatment resistance in SRL‐naïve patients. The gene discussed is CD8A; the disease is growth hormone-secreting pituitary adenoma.